Human Liver Model Market Report 2025

The human liver model market size has grown rapidly in recent years. It will grow from $2.34 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to drug development needs, advancements in biotechnology, animal testing alternatives, rising liver diseases, regulatory demands.

The human liver model market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to ai and machine learning integration, patient-derived liver models, bioengineering breakthroughs, drug safety and toxicity testing requirements, virtual clinical trials. Major trends in the forecast period include multi-organ models integration, 3d bioprinting innovations, high-throughput screening capability, enhanced vascularization and blood flow, ethical and regulatory compliance.

The growth of the human liver model market is anticipated to be driven by the increasing incidence of liver disease. Liver disease encompasses various disorders that affect the proper functioning of the liver. The emerging area of research involving human liver models holds the potential to enhance understanding of liver diseases and improve drug development. Consequently, the escalating cases of liver diseases are fostering the expansion of the human liver model market. For instance, in September 2022, Caner Australia reported approximately 2,905 new cases of liver cancer diagnosed in Australia in 2022, highlighting the significance of addressing liver-related health concerns. The rising prevalence of liver disease underscores the crucial role of human liver models in advancing medical research and therapeutic strategies.

The growth of the human liver model market is further expected to be propelled by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, treatments, or drugs in humans, frequently employ human liver models to simulate drug metabolism and assess hepatotoxicity in the context of pharmaceutical development. As of May 2023, there are 452,604 registered clinical trials globally, signifying a substantial increase from previous counts. The surge in clinical trials emphasizes the growing demand for human liver models in facilitating robust research practices and advancing drug discovery initiatives.

A prominent trend in the human liver model market is the focus on product innovation by major companies. Companies operating in this market are actively engaged in developing innovative products to enhance their market positioning. In April 2023, LifeNet Health Life Sciences introduced TruVivo, a groundbreaking liver system composed entirely of human cells. TruVivo represents a 2D+ solution that combines the robust data associated with 3D models with the flexibility and simplicity of a 2D model, offering a significant advancement in liver research and drug development.

Major players in the human liver model market are directing their efforts toward the development of advanced systems, particularly single-organ higher throughput (HT) systems. These innovative systems aim to improve the adoption of predictive human liver models and provide a competitive advantage. For instance, in February 2023, UK-based organ-on-a-chip company CN Bio launched PhysioMimix with Liver-48 plate, a single-organ higher throughput (HT) system designed to overcome challenges in the adoption of predictive human liver models for drug discovery. The Liver-48 plate, a multi-chip consumable, facilitates larger-scale comparative studies on drug disposition, efficacy, and safety.

In April 2023, AnaBios Corporation, a biotechnology research firm, acquired Cell Systems for an undisclosed amount. This acquisition is designed to enhance AnaBios' capabilities in drug discovery and development by integrating Cell Systems' advanced cell-based technologies. As a result, this move strengthens AnaBios' portfolio in human-relevant models, allowing for more accurate predictions of drug efficacy and safety. Cell Systems is a biotechnology research company based in the US.

Major companies operating in the human liver model market include Corning Incorporated, EISCO Scientific LLC, BioIVT LLC, Cyprotex plc, Emulate Inc., Cellink AB, Nortis Inc., InSphero AG, CN Bio Innovations Ltd., TissUse GmbH, Ascendance Biotechnology Inc., HemoShear Therapeutics Inc., Cyfuse Biomedical, MIMETAS BV, Biopredic International Sarl, ZenBio, Hurel Corporation, Regenovo, Pandorum, Organovo Holdings Inc., BICO Group, Hepregen Corporation, Kirkstall Ltd., HepaLife Technologies Inc., Cellaïon SA.

North America was the largest region in the human liver model market in 2024. The regions covered in the human liver model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human liver model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human liver model represents a dual-lobed model of the human liver, primarily responsible for filtering blood from the digestive tract. It is utilized to illustrate and assess the toxic effects of drug candidates on the liver.

The primary product types of human liver models include liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. Liver organoids are 3D structures generated from stem cells that self-organize through mechanisms similar to those in vivo. These models find applications in education, drug discovery, and other fields, and are employed by research institutes, pharmaceutical companies, and other entities.

The human liver model market research report is one of a series of new reports that provides human liver model market statistics, including human liver model industry global market size, regional shares, competitors with a human liver model market share, detailed human liver model market segments, market trends and opportunities, and any further data you may need to thrive in the human liver model industry. This human liver model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human liver model market consists of sales of 3B scientific liver and prime baker fiber liver model. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.